PixarBio Corporation

PXRB

US72582G1094

Pharmaceuticals

Delayed OTC Markets Other stock markets 03:17:43 2023-06-27 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2018	PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain	CI
2018	Pixarbio Corporation Announces the Removal of Katrin Holzhaus as Chief Administration Officer and Corporate Secretary of the Company	CI

PixarBio Corporation Promotes Jason Criscione to Chief Technology Officer

June 25, 2015 at 06:00 am EDT

PixarBio Corporation announced that Jason Criscione has been promoted to Chief Technology Officer. Since March 2014, Dr. Criscione has led the development and translation of PixarBio's drug delivery platform.

Latest news about PixarBio Corporation

PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain	18-02-27	CI
Pixarbio Corporation Announces the Removal of Katrin Holzhaus as Chief Administration Officer and Corporate Secretary of the Company	18-02-15	CI
PixarBio Corporation announced that it has received $0.411258 million in funding	18-02-11	CI
PixarBio Corporation Announces Change of Directors	17-12-28	CI
PixarBio Corp Announces Resignation of Derek Bridges Member of Board of Directors	17-12-22	CI
PixarBio Corporation announced a financing transaction	17-11-12	CI
PixarBio Corporation announced that it has received $0.0885 million in funding	17-06-29	CI
PixarBio Corporation announced a financing transaction	17-06-14	CI
PixarBio Corporation announced that it has received $0.21 million in funding	17-05-01	CI
PixarBio Corporation announced a financing transaction	17-04-16	CI
Pixarbio Corporation Announces Termination of Robert S. Langer as a Member of Scientific Advisory Board	17-03-10	CI
PixarBio Corporation Announces Management Changes	17-02-09	CI
PixarBio Corporation cancelled the acquisition of InVivo Therapeutics Holdings Corp..	17-01-22	CI
PixarBio Corporation announced that it has received $0.3 million in funding	17-01-22	CI
Henry Sargent acquired Buddhi Mat LLC from PixarBio Corporation.	17-01-04	CI
PixarBio Corporation made a bid to acquire InVivo Therapeutics Holdings Corp. for $77 million.	17-01-02	CI
PixarBio Corporation Establishes the JP Reynolds Research Center in Woburn, MA	16-12-21	CI
PixarBio Corporation Appoints Steve Chartier as Chief Operating Officer	16-12-20	CI
PixarBio Corporation Appoints Barry Belfer as Senior Vice President of Finance	16-11-07	CI
PixarBio Corporation Auditor Raises 'Going Concern' Doubt	16-11-03	CI
BMP Holdings Inc. completed the acquisition of BMP Holdings Inc. in a reverse merger transaction.	16-10-29	CI
PixarBio Corporation announced that it has received $7.19 million in funding	16-10-29	CI
Pixarbio Corporation Promotes Ken Stromsland to Vice-President, CIO External Communications	16-10-20	CI
BMP Holdings Inc. agreed to acquire BMP Holdings Inc. in a reverse merger transaction.	16-08-23	CI
BMP Holdings Inc. announced that it has received $0.22 million in funding from PixarBio Corporation	16-08-18	CI

Chart PixarBio Corporation

Duration

Period

More charts

Company Profile

PixarBio Corporation is a specialty pharmaceutical company that is focused on the pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. The Companyâs lead product platform, NeuroRelease, is a novel biodegradable microparticle delivery system for the delivery of non-opiate prescription paid drugs. NeuroRelease offers sustained therapeutic pre-clinical release over time of a non-opiate drug for post-operative, acute, and chronic pain in pre-clinical models involving rodents and pigs. NeuroRelease treats multiple conditions, including pain, Parkinsonâs disease, epilepsy, and spinal cord injury. NeuroRelease is biodegradable, and it is non-toxic so it can be re-injected to extend treatment timelines. Its Injectable NeuroScaffold is a platform to advance from acute neuro-protective spinal cord injury treatment to a regeneration treatment for chronic spinal cord injury.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
PIXARBIO CORPORATION	-.--%	81
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.24%	45.32B
OTSUKA HOLDINGS CO., LTD.	+34.85%	24.51B
SANDOZ GROUP AG	+29.56%	16.85B
CIPLA LIMITED	+21.32%	14.62B
ZYDUS LIFESCIENCES LIMITED	+70.51%	14.16B
THE MEDICINES COMPANY	-0.05%	6.79B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.74%	5.82B
STADA ARZNEIMITTEL	-8.87%	5.73B
GEDEON RICHTER	+10.29%	4.93B

Generic Pharmaceuticals